BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
| RegularNews read more...
Nov 02, 2022
VOLUNTARY ANNOUNCEMENT - UPDATE REGARDING
RECENT BUSINESS DEVELOPMENTS
| Announcements and Notices read more...
Nov 02, 2022
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
| RegularNews read more...
Oct 31, 2022
Next Day Disclosure Return
| Next Day Disclosure Returns read more...
Oct 31, 2022
COMPANY INFORMATION SHEET
| Announcements and Notices read more...
Oct 30, 2022
Next Day Disclosure Return
| Next Day Disclosure Returns read more...
Oct 28, 2022
DATE OF AUDIT COMMITTEE MEETING
| Announcements and Notices read more...
Oct 26, 2022
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America
| RegularNews read more...
Oct 14, 2022
VOLUNTARY ANNOUNCEMENT - UPDATE REGARDING
RECENT BUSINESS DEVELOPMENTS
| Announcements and Notices read more...
Oct 14, 2022
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL
| RegularNews read more...
Oct 12, 2022
VOLUNTARY ANNOUNCEMENT - UPDATE REGARDING RECENT BUSINESS DEVELOPMENTS
| Announcements and Notices read more...
Oct 12, 2022
BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial
| RegularNews read more...
Oct 09, 2022
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2022
| Monthly Returns read more...
Oct 05, 2022
GRANT OF SHARE OPTIONS
| Announcements and Notices read more...
Oct 03, 2022
Next Day Disclosure Return
| Next Day Disclosure Returns read more...
Sep 29, 2022
Next Day Disclosure Return
| Next Day Disclosure Returns read more...
Sep 28, 2022
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
| Announcements and Notices read more...
VOLUNTARY ANNOUNCEMENT - UPDATE REGARDING
RECENT BUSINESS DEVELOPMENTS
| Announcements and Notices read more...
Sep 19, 2022
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
| RegularNews read more...
